Abstract
Techniques employing monoclonal antibodies (mAbs) are widely used in the initial development phase of biologics. The usefulness of mAbs in basic RA research has been established based on their characteristics, including specificity of binding, homogeneity, and ability to be produced on a large scale. MAb immunoglobulins are the starting material for the generation of smaller antibody fragments and other engineered immunomodulatory antibodies. In this chapter, the basic hybridoma technique, which is a well-established and feasible method for the production of mAbs involving animal immunization, cell fusion, hybridoma screening, expanding positive hybridomas, and purification, is introduced. Aiming at specific affinity to a membrane protein, synthetic proteoliposomes are used in the immunization and screening steps.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Davis BP, Ballas ZK (2017) Biologic response modifiers: indications, implications, and insights. J Allergy Clin Immunol 139:1445–1456
Evans CH, Ghivizzani SC, Robbins PD (2013) Arthritis gene therapy and its tortuous path into the clinic. Transl Res 161:205–216
Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA (2011) A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 90:828–835
Kalden JR (2016) Emerging therapies for rheumatoid arthritis. Rheumatol Ther 3:31–42
Hutchings CJ, Koglin M, Marshall FH (2010) Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2:594–606
Liu S, Hasegawa H, Takemasa E, Suzuki Y, Oka K, Kiyoi T et al (2017) Efficiency and safety of CRAC inhibitors in human rheumatoid arthritis xenograft models. J Immunol 199:1584–1595
Takeda H, Ogasawara T, Ozawa T, Muraguchi A, Jih PJ, Morishita R et al (2015) Production of monoclonal antibodies against GPCR using cell-free synthesized GPCR antigen and biotinylated liposome-based interaction assay. Sci Rep 5:11333
Tomita M, Tsumoto K (2011) Hybridoma technologies for antibody production. Immunotherapy 3:371–380
Kohler G, Howe SC, Milstein C (1976) Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol 6:292–295
Apostolico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS (2016) Adjuvants: classification, modus operandi, and licensing. J Immunol Res 2016:1459394
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Takemasa, E., Liu, S. (2024). Production of Neutralizing Antibody. In: Liu, S. (eds) Rheumatoid Arthritis. Methods in Molecular Biology, vol 2766. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3682-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3682-4_11
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3681-7
Online ISBN: 978-1-0716-3682-4
eBook Packages: Springer Protocols